Highly sensitive and specific detection of HBV DNA and drug resistance mutations utilizing the PCR-based CRISPR-Cas13a system.

[1]  R. Chou,et al.  WHO guidelines on testing for hepatitis B and C – meeting targets for testing , 2017, BMC Infectious Diseases.

[2]  W. Choe,et al.  Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naïve Korean patients infected with genotype C2 , 2017, World journal of gastroenterology.

[3]  Aviv Regev,et al.  Nucleic acid detection with CRISPR-Cas13a/C2c2 , 2017, Science.

[4]  Jennifer A. Doudna,et al.  Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection , 2016, Nature.

[5]  P. Hu,et al.  Comparison of droplet digital PCR to real-time PCR for quantification of hepatitis B virus DNA , 2016, Bioscience, biotechnology, and biochemistry.

[6]  Eric S. Lander,et al.  C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector , 2016, Science.

[7]  Yueping Liu,et al.  Rapid and quantitative detection of hepatitis B virus. , 2015, World journal of gastroenterology.

[8]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[9]  D. Sinn,et al.  Hepatocellular carcinoma risk in chronic hepatitis B virus–infected compensated cirrhosis patients with low viral load , 2015, Hepatology.

[10]  Wei Zhao,et al.  Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B. , 2015, World journal of gastroenterology.

[11]  B. Cai,et al.  Incidence of natural resistance mutations in naïve chronic hepatitis B patients: A systematic review and meta‐analysis , 2015, Journal of gastroenterology and hepatology.

[12]  Christopher M. Hindson,et al.  Absolute quantification by droplet digital PCR versus analog real-time PCR , 2013, Nature Methods.

[13]  V. Wong,et al.  Predictors of relapse in chronic hepatitis B after discontinuation of anti‐viral therapy , 2011, Alimentary pharmacology & therapeutics.

[14]  F. Liu,et al.  Poor durability of lamivudine effectiveness despite stringent cessation criteria: A prospective clinical study in hepatitis B e antigen‐negative chronic hepatitis B patients , 2011, Journal of gastroenterology and hepatology.

[15]  P. Torres,et al.  Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain , 2010, Transfusion.

[16]  Lei Li,et al.  The efficacy of individual‐donation and minipool testing to detect low‐level hepatitis B virus DNA in Taiwan , 2010, Transfusion.

[17]  Y. Liaw.  Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. , 2009, Journal of hepatology.

[18]  F. Zoulim,et al.  Management and prevention of drug resistance in chronic hepatitis B , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[19]  M. Capobianchi,et al.  Comparison of Versant HBV DNA 3.0 and COBAS AmpliPrep-COBAS TaqMan assays for hepatitis B DNA quantitation: Possible clinical implications. , 2007, Journal of virological methods.

[20]  G. Colucci,et al.  COBAS AmpliPrep-COBAS TaqMan Hepatitis B Virus (HBV) Test: a Novel Automated Real-Time PCR Assay for Quantification of HBV DNA in Plasma , 2007, Journal of Clinical Microbiology.

[21]  J. Allain.  Occult hepatitis B virus infection. , 2004, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[22]  Y. Lim,et al.  Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion , 2003, Gut.

[23]  A. Lok,et al.  Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection , 2002 .

[24]  A. Lok,et al.  Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection , 2002, Hepatology.

[25]  M. Poljak,et al.  Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). , 2016, The Journal of infectious diseases.

[26]  Fan Shen,et al.  Next generation digital PCR measurement of hepatitis B virus copy number in formalin-fixed paraffin-embedded hepatocellular carcinoma tissue. , 2015, Clinical chemistry.

[27]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[28]  John Rockfeller McCormick Memorial Fund.  Journal of infectious diseases , 1997 .